SAN FRANCISCO (EGMN) - Use of new, more expensive therapies for prostate cancer increased rapidly during a recent 4-year period, despite a lack of consensus on their effectiveness relative to that of older, less expensive therapies, researchers reported at a symposium on genitourinary cancers. In a cross-sectional sample of more than 58,000 older U.S. men with nonmetastatic prostate cancer, the use of minimally invasive radical prostatectomy increased 19-fold, of intensity-modulated radiation therapy...